• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗利什曼原虫/抗结核的7-取代2-硝基咪唑并恶嗪的新型连接体变体具有更高的溶解度。

Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.

作者信息

Thompson Andrew M, O'Connor Patrick D, Yardley Vanessa, Maes Louis, Launay Delphine, Braillard Stephanie, Chatelain Eric, Wan Baojie, Franzblau Scott G, Ma Zhenkun, Cooper Christopher B, Denny William A

机构信息

Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.

Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.

出版信息

ACS Med Chem Lett. 2021 Jan 21;12(2):275-281. doi: 10.1021/acsmedchemlett.0c00649. eCollection 2021 Feb 11.

DOI:10.1021/acsmedchemlett.0c00649
PMID:33603975
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7883471/
Abstract

Antitubercular 7-substituted 2-nitroimidazo[2,1-][1,3]oxazines were previously shown to exhibit potent antileishmanial and antitrypanosomal activities, culminating in a new clinical investigational drug for visceral leishmaniasis (DNDI-0690). To offset development risks, we continued to seek further leads with divergent candidate profiles, especially analogues possessing greater aqueous solubility. Starting from an efficacious monoaryl derivative, replacement of the side chain ether linkage by novel amine, amide, and urea functionality was first explored; the former substitution was well-tolerated and but elicited marginal alterations to solubility (except through a less stable benzylamine), whereas the latter groups resulted in significant solubility improvements (up to 53-fold) but an antileishmanial potency reduction of at least 10-fold. Ultimately, we discovered that -carbamate offered a more optimal balance of increased solubility, suitable metabolic stability, excellent oral bioavailability (100%), and strong efficacy in a visceral leishmaniasis mouse model (97% parasite load reduction at 25 mg/kg).

摘要

抗结核的7-取代2-硝基咪唑并[2,1-][1,3]恶嗪先前已显示出有效的抗利什曼原虫和抗锥虫活性,最终开发出一种用于内脏利什曼病的新型临床研究药物(DNDI-0690)。为了降低开发风险,我们继续寻找具有不同候选特征的更多先导化合物,特别是具有更高水溶性的类似物。从一种有效的单芳基衍生物开始,首先探索用新型胺、酰胺和脲官能团取代侧链醚键;前一种取代耐受性良好,但对溶解度的影响很小(通过不太稳定的苄胺除外),而后一种基团导致溶解度显著提高(高达53倍),但抗利什曼原虫效力降低至少10倍。最终,我们发现氨基甲酸酯在增加溶解度、合适的代谢稳定性、优异的口服生物利用度(100%)以及在内脏利什曼病小鼠模型中的强效疗效(25 mg/kg时寄生虫负荷降低97%)方面提供了更优的平衡。

相似文献

1
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.抗利什曼原虫/抗结核的7-取代2-硝基咪唑并恶嗪的新型连接体变体具有更高的溶解度。
ACS Med Chem Lett. 2021 Jan 21;12(2):275-281. doi: 10.1021/acsmedchemlett.0c00649. eCollection 2021 Feb 11.
2
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.抗利什曼原虫 7-取代 2-硝基咪唑并恶嗪先导物的杂芳基醚类似物可降低 hERG 风险:体外和体内评估。
Eur J Med Chem. 2021 Jan 1;209:112914. doi: 10.1016/j.ejmech.2020.112914. Epub 2020 Oct 10.
3
Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.硝咪唑并恶唑类化合物 DNDI-VL-2098:一种治疗内脏利什曼病的有效口服前临床候选药物。
J Antimicrob Chemother. 2015 Feb;70(2):518-27. doi: 10.1093/jac/dku422. Epub 2014 Nov 10.
4
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.7-取代的2-硝基-5,6-二氢咪唑并[2,1-b][1,3]恶嗪:新型抗结核药物成为内脏利什曼病的新临床前候选药物。
J Med Chem. 2017 May 25;60(10):4212-4233. doi: 10.1021/acs.jmedchem.7b00034. Epub 2017 May 11.
5
Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains.含杂环侧链的抗结核 2-硝基咪唑恶嗪的合成及构效关系。
J Med Chem. 2010 Jan 28;53(2):855-66. doi: 10.1021/jm901378u.
6
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.(6R)-2-硝基-6-[4-(三氟甲氧基)苯氧基]-6,7-二氢-5H-咪唑并[2,1-b][1,3]恶嗪(DNDI-8219)的开发:一种新的内脏利什曼病治疗先导化合物。
J Med Chem. 2018 Mar 22;61(6):2329-2352. doi: 10.1021/acs.jmedchem.7b01581. Epub 2018 Mar 6.
7
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).酰胺、氨基甲酸酯和脲连接的类似物与结核药物(6S)-2-硝基-6-{[4-(三氟甲氧基)苄基]氧基}-6,7-二氢-5H-咪唑并[2,1-b][1,3]恶嗪(PA-824)的构效关系。
J Med Chem. 2012 Jan 12;55(1):312-26. doi: 10.1021/jm2012276. Epub 2011 Dec 29.
8
Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.重新定位抗结核 6-硝基-2,3-二氢咪唑并[2,1-b][1,3]恶唑类药物治疗被忽视热带病:内脏利什曼病临床前候选药物的结构活性研究。
J Med Chem. 2016 Mar 24;59(6):2530-50. doi: 10.1021/acs.jmedchem.5b01699. Epub 2016 Mar 8.
9
SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.抗利什曼原虫的N(2),N(4)-二取代喹唑啉-2,4-二胺的SAR优化
Bioorg Med Chem. 2015 Aug 15;23(16):5182-9. doi: 10.1016/j.bmc.2015.02.020. Epub 2015 Feb 18.
10
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).氮杂和二氮杂联苯类似物的合成及结构活性关系,该类似物为抗结核药物(6S)-2-硝基-6-[[4-(三氟甲氧基)苄基]氧基]-6,7-二氢-5H-咪唑并[2,1-b][1,3]恶嗪(PA-824)。
J Med Chem. 2010 Dec 9;53(23):8421-39. doi: 10.1021/jm101288t. Epub 2010 Nov 11.

引用本文的文献

1
Exploring Benzo[h]chromene Derivatives as Agents against Protozoal and Mycobacterial Infections.探索苯并[h]色烯衍生物作为抗原生动物和分枝杆菌感染的药物。
Pharmaceuticals (Basel). 2024 Oct 16;17(10):1375. doi: 10.3390/ph17101375.
2
Current leishmaniasis drug discovery.当前利什曼病药物研发
RSC Med Chem. 2022 Aug 26;13(9):1029-1043. doi: 10.1039/d1md00362c. eCollection 2022 Sep 21.
3
Amino-Substituted 3-Aryl- and 3-Heteroarylquinolines as Potential Antileishmanial Agents.氨基取代的 3-芳基和 3-杂芳基喹啉类化合物作为潜在的抗利什曼原虫药物。
J Med Chem. 2021 Aug 26;64(16):12152-12162. doi: 10.1021/acs.jmedchem.1c00813. Epub 2021 Aug 6.

本文引用的文献

1
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.抗利什曼原虫 7-取代 2-硝基咪唑并恶嗪先导物的杂芳基醚类似物可降低 hERG 风险:体外和体内评估。
Eur J Med Chem. 2021 Jan 1;209:112914. doi: 10.1016/j.ejmech.2020.112914. Epub 2020 Oct 10.
2
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.发现并表征临床候选药物 LXE408 为一种利什曼原虫选择性蛋白酶体抑制剂,用于治疗利什曼病。
J Med Chem. 2020 Oct 8;63(19):10773-10781. doi: 10.1021/acs.jmedchem.0c00499. Epub 2020 Jul 29.
3
The proteasome as a target for protozoan parasites.蛋白酶体作为原生动物寄生虫的靶标。
Expert Opin Ther Targets. 2019 Nov;23(11):903-914. doi: 10.1080/14728222.2019.1685981. Epub 2019 Nov 4.
4
Pretomanid: First Approval.苯并异噻唑酮(pretomanid):首次批准。
Drugs. 2019 Nov;79(16):1797-1803. doi: 10.1007/s40265-019-01207-9.
5
Need for sustainable approaches in antileishmanial drug discovery.抗利什曼原虫药物发现中可持续方法的必要性。
Parasitol Res. 2019 Oct;118(10):2743-2752. doi: 10.1007/s00436-019-06443-2. Epub 2019 Aug 31.
6
Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis.硝咪唑类化合物 DNDI-0690 在皮肤利什曼病小鼠模型中的药代动力学和药效学研究。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00829-19. Print 2019 Sep.
7
Optimisation of a key cross-coupling reaction towards the synthesis of a promising antileishmanial compound.优化一种关键交叉偶联反应以合成一种有前景的抗利什曼原虫化合物。
Tetrahedron Lett. 2019 May 2;60(18):1243-1247. doi: 10.1016/j.tetlet.2019.03.068.
8
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis.新型苯并硼烷、硝基咪唑和氨基吡唑类化合物对实验性皮肤利什曼病具有活性。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:129-138. doi: 10.1016/j.ijpddr.2019.02.002. Epub 2019 Feb 26.
9
Walking a tightrope: drug discovery in visceral leishmaniasis.走钢丝:内脏利什曼病的药物发现。
Drug Discov Today. 2019 May;24(5):1209-1216. doi: 10.1016/j.drudis.2019.03.007. Epub 2019 Mar 12.
10
Clinical and veterinary trypanocidal benzoxaboroles target CPSF3.临床和兽医杀锥虫苯并恶唑类化合物靶向 CPSF3。
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):9616-9621. doi: 10.1073/pnas.1807915115. Epub 2018 Sep 5.